Menopause, Platelet-rich Plasma, Estrogen Replacement Therapy, Vaginal Atrophy
Conditions
Brief summary
The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia. The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.
Interventions
DRUGVaginal estrogen supplement
Daily vaginal estrogen supplement, then twice per week. Continue for three months.
PROCEDUREPlatelet-rich plasma injection
Monthly platelet-rich plasma injection for three months
Sponsors
Mackay Memorial Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Women with menopause * Patients with symptoms of genitourinary syndrome of menopause
Exclusion criteria
* Genitourinary bleeding or infection without definitive diagnosis * Coagulopathy * Allergy to medication or therapy related with the treatment * Chronic disease that might influence outcome * Using medication that might influence outcome in 30 days * Using hormone or steroid within 8 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Female Sexual Function Index (FSFI) | 2022/8/10-2024/2/28 | A brief multidimensional scale for assessing sexual function in women. |
| Visual analogue scale (VAS) | 2022/8/10-2024/2/28 | Changes in GSM symptoms include vaginal dryness, dyspareunia, itching, burning, dysuria |
| Vaginal health index score (VHIS) | 2022/8/10-2024/2/28 | One of the most commonly used scores for the evaluation of vaginal elasticity, secretions, pH, the presence of petechiae on the epithelial mucosa, and hydration |
Countries
Taiwan
Contacts
Primary ContactHui-Hsuan Lau
Outcome results
None listed